Home
overview

For the latest COVID-19 Travel restrictions and recommendations please click here

SMi’s 22nd Annual Conference
Pain Therapeutics
4 - 5 May, 2022 | London, UK
-------------------------------------------------------------------------
To register your interest or to get involved please contact:Join Europe’s leading Pain Therapeutics Conference, to explore the cutting-edge research of novel therapeutic targets in the pipeline of leading pharmaceutical companies and to discuss solutions for the challenges of clinical trial design and conduct.


The 22nd annual conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments, using VR and Medical Devices that carry out non-invasive nerve stimulation. Industry leaders will uncover the latest advancements in the field, highlighting the use of opioids and the future for cannabinoids within the pain therapeutics field. Furthermore, policy experts will provide an essential regulatory perspective for this year’s agenda, providing an exciting and comprehensive insight into the pain therapeutics market.


New case studies and regulatory perspectives will bring together the challenges and successes of both pre-clinical and clinical development to equip you with the necessary knowledge to advance the pain therapeutic industry.
 

Chief Executive Officer, Chief Scientific Officers, Chief Medical Officers, Managing Directors, CEO, Head of Department, Principal Research Scientists, Clinical lead, Clinical Operations in the following fields:

  • Pain and Migraine
  • Inflammation
  • Chronic Pain
  • Neuropathic Pain
  • Analgesic pre-clinical development
  • Anaesthesia and Pain Management
  • CNS clinical trials
  • Ion Channel Pharmacology
  • Pharmacology Intelligence
  • Translational science
  • Drug development
  • Exploratory development

Algiax Pharmaceuticals Gmbh; Allergan; Asahi Kasei Pharma Corporation; AstraZeneca; AstraZeneca R&D Biopharmaceuticals; Cambridge Cognition Ltd.; Clexio Biosciences; Collegium Pharmaceuticals; Eli Lilly & Company; Eli Lilly and Company; Genentech; GlaxoSmithKline (GSK); Grunenthal Gmbh; Grünenthal GmbH; GSK; IPSEN; Ipsen Bioinnovation; Ipsen Innovation; Johns Hopkins University; Levicept Ltd; Lotus Clinical Research, LLC; LotusCR; McGill University; McGill University (Human Pain Genetics Lab); MD Biosciences; MD Biosciences Inc; Metys Pharmaceuticals; Metys Pharmaceuticals AG; Metys Pharmaceuticals Ltd; National Institute of Neurological Disorders and Stroke; National Institutes of Health; Navega Therapeutics; Neumentum; Neurana Pharmaceuticals; NINDS/NIH; Novaremed; Orion Pharma; Sygnature Discovery ; Taro Pharmaceutical Industries LTD.; TEVA Hungary; Teva Pharmaceuticals; THE ANN HAYES CONSULTANCY; The Johns Hopkins Hospital; Transpharmation Ltd; Vapogenix; Vifor Pharma Ltd;

Conference programme

8:30 Registration and Coffee

9:00 Chair's Opening Remarks

Richard Malamut

Richard Malamut, Chief Medical Officer and EVP, Collegium Pharmaceuticals

9:10 “Pain is Pain – or is it?” – Perspectives on Chronic Pain

Arun Bhaskar

Arun Bhaskar, President, The British Pain Society

  • Chronic pain results in major health and welfare expenditure, but its management is not well supported
  • The multifactorial biopsychosocial aspects of pain is often not acknowledged resulting in poor management
  • Pharmacological management are often targeting symptom control rather than treating the cause
  • Multimodal interdisciplinary management is needed but is delivered piece-meal
  • 9:50 Using transcriptomics to gain a deeper understanding of chronic pain diseases

    Candler Paige

    Candler Paige, Chief Executive Officer, Doloromics

  • Spatially characterizing the dorsal root ganglion (DRG)
  • Generating uniquely rich multi-omics datasets, which will combine spatial transcriptomics information, bulk RNA sequencing, and single nucleus split-sequencing
  • The benefits and importance of collaboration for developing novel therapeutics for chronic pain conditions
  • 10:30 Morning Coffee

    11:00 People suffering from Fibromyalgia: Challenges in clinical study setting before and during Covid-19 pandemic

    Domenico Merante

    Domenico Merante, Clinical Development Lead of Nephrology and Orphan Diseases, Vifor Pharma Ltd

  • An overview into how the covid-19 pandemic has affected patients with Fibromyalgia
  • Understanding the changes in treatments and the impact on the clinical setting
  • Challenges of patients suffering with fibromyalgia before the pandemic compared to during
  • How the treatment has improved in recent months, where are we now?
  • 11:40 Preventative medication for the treatment of migraine. The Role of CGRP in migrane

    Michael Seminerio

    Michael Seminerio, Senior Director, US Medical Lead, Teva Pharmaceuticals

  • Oral CGRP inhibitors and how they work in the treatment of migraines
  • Advantages in comparison to needle based preventatives
  • Qulipta in chronic migraine prevention – an update on this trial
  • The use of botox in the prevention of headaches
  • 12:20 Networking Lunch

    13:20 AOBiome’s drug development program for the treatment of Pruritus associated with Atopic Dermatitis

    Todd Krueger

    Todd Krueger, President and CEO, AOBiome

  • An introduction to Atopic Dermatitis and Pruritus
  • Discussion of mechanisms and pre-clinical development work
  • Review of clinical results and the challenges faced
  • The future outlook for this research
  • 14:00 A case study: Acute Muscle Spasm Phase III Study

    Randall Kaye

    Randall Kaye, Chief Medical Officer, Neurana Pharmaceuticals

  • Tolperisone history
  • Background on use of skeletal muscle relaxants in acute pain
  • Pivotal Phase 3 Study results (safety and efficacy)
  • Study Implications
  • 14:40 Afternoon Tea

    15:10 First-in-class HCn1 selective inhibitors for the management of neuropathic pain

    Steve Fox

    Steve Fox, Chairman, Akelos Inc

  • An introduction to Chemotherapy Induced Peripheral Neuropathy (CIPN)
  • The current treatments for these patients and their challenges
  • Target engagement HCN1 in human sensory neurons
  • Financing optimisation into first-in-human clinical trials
  • 15:50 the nIH HeAl Initiative/national Institute of neurological Disorders and Stroke's Early Phase Pain Investigation Clinical Network (EPPIC-Net): Year 2 Update

  • Part of the NIH Helping to End Addiction Long-term (HEAL) InitiativeSM , the Early Phase Pain Investigation Clinical Network (EPPIC-Net) provides complete phase 2 clinical trials for novel and repurposed pain therapeutics (including drugs and devices) selected through a rigorous application and review process. Trials can incorporate novel trial design, proof-of-concept testing, and biomarker validation and are provided at no cost to the applicant. the applicant retains intellectual property rights to their asset
  • EPPIC-Net’s clinical trial infrastructure includes a Clinical Coordinating Center, Data Coordinating Center, and 12 Specialized Clinical Centers (Hubs and Spokes) across the US with broad outreach to pain populations. EPPIC-Net investigators bring broad pain clinical and
  • research expertise
  • In the first 2 years EPPIC-net has been open to applications, 3 asset trials have been funded; one trial is now open to enrollment. EPPICNet is also developing an innovative master platform protocol for
  • therapeutics targeted to painful diabetic peripheral neuropathy
  • EPPIC-Net accepts and reviews applications from academic and industry sponsors worldwide, at any time on a rolling basis
  • Jennifer Beierlein

    Jennifer Beierlein, Health Program Specialist, National Institute of Neurological Disorders and Stroke National Institutes of Health

    Barbara Karp

    Barbara Karp, Program Director, EPPIC-Net, National Institutes Of Health

    16:30 Chair's Closing Remarks and Close of Day One

    Richard Malamut

    Richard Malamut, Chief Medical Officer and EVP, Collegium Pharmaceuticals

    8:30 Registration and Coffee

    9:00 Chair's Opening Remarks

    Richard Malamut

    Richard Malamut, Chief Medical Officer and EVP, Collegium Pharmaceuticals

    9:10 Personalized Analgesics® research: a novel network biology approach to transform pain R&D

    Mark J. Field

    Mark J. Field, CEO & Founder, EptivA Therapeutics

  • Chronic pain is a huge burden to patients and society as a whole with a lack of safe and effective analgesic treatments
  • Innovation in the pain area is extremely low with few new medicines reaching patients due to exceptionally high attrition rates in R&D.
  • New transformative approaches for pain drug development are required to improve the probability of R&D success and encourage increased investments into the area
  • This presentation will describe a novel Personalized Analgesics® network biology approach to link research targets to disease, based on our development of the Pain Landscape® the Pain diseasome®
  • Creating R&D methods that link the mechanistic research target to the most appropriate disease can develop more precision-analgesics de-risking R&D and helping create improved solutions for patients
  • 9:50 Challenges in Analgesics development for Acute and Chronic Pain

    Ilona Steigerwald

    Ilona Steigerwald, Chief Medical Officer, SVP, Neumentum

  • New Mechanisms and NCEs - Where do we Stand?
  • Opioid Replacement and Sparing Strategies
  • Review of Regulatory Environment
  • 10:30 Morning Coffee

    11:00 Proof of target engagement of new analgesics in early phase clinical drug studies in healthy volunteers

    Geert Jan Groeneveld

    Geert Jan Groeneveld, CSO/CMO, Centre for Human Drug Research

  • Demonstrating target engagement early in in the clinical phase of drug development is essential and can assist in streamlining the process of drug development by selecting the most promising candidates early and stopping work on the less promising ones.
  • Demonstrating target engagement in the development of new analgesics can be done using evoked pain tests in healthy subjects, by adding patients with pain to the early clinical pharmacology studies, or using measurement methods that mechanistically demonstrate the intended pharmacology
  • Examples of each three models will be given. A special role will be played by CHDR’s pain test battery called the PainCart®.
  • Results of recent studies where PainCart® was combined with challenges leading to lowered pain thresholds in healthy subjects than can be considered forms of centrally induced hyperalgesia will be presented.
  • 11:40 The next Generation of Opioids in development.

    Lynn Kirkpatrick

    Lynn Kirkpatrick, President and CEO, Ensysce Biosciences Inc.

  • Chronic pain – it’s not going away.
  • Abuse protection vs deterrence – what is the difference?
  • 2 new classes of safer opioids – “tAAP and MPAR” – what is behind the acronyms?
  • Clinical data on PF614 – a tAAP opioid from Ensysce Biosciences.
  • 12:20 Networking Lunch

    13:20 Novel Plant-inspired therapeutic for Pain

    Andrea Small-Howard

    Andrea Small-Howard, President & Chief Science Officer, GB Sciences, Inc.

  • Plant-based remedies for pain have been a part of traditional Medicine for thousands of years
  • Cannabis-based remedies for pain are emerging as a viable option with improved safety profi les
  • Other plant-based remedies are being adapted for the prescription drug market to reduce our reliance on opioids.
  • 14:00 Using opioids to treat opioid use disorder

    Joshua Cohen

    Joshua Cohen, Chief Medical Officer, Braeburn

  • The opioid epidemic: A worsening public health crisis
  • The science behind opioid use disorder
  • Current treatment paradigms and patient unmet needs
  • Medications for opioid use disorder (MOUDs) – scientific rationale and clinical data
  • 14:40 Afternoon Tea

    15:10 Long-term consequences of silencing pain pathways with novel Botulinum constructs

    Maria  Maiaru

    Maria Maiaru, Lecturer in Pharmacology, University of Reading

  • There is an urgent need for more effective and safer treatment for chronic pain.
  • A single intrathecal injection of botulinum toxin conjugate produces a long-lasting pain relief in a mouse model of neuropathic pain without toxic side effects.
  • This strategy might be a safer and effective approach for relieving chronic pain while avoiding the adverse events associated with repeated chronic drug administration.
  • 15:50 Opioids and Cannabinoids, traditional or novel treatments?

  • The benefits and dangers of using opioids for the treatment of chronic pain
  • The use of cannabinoids and how this is different to opioids
  • Benefits and challenges of both opioids and cannabinoids
  • The future of the use of these compounds and what it means for chronic pain
  • Richard Malamut

    Richard Malamut, Chief Medical Officer and EVP, Collegium Pharmaceuticals

    Joshua Cohen

    Joshua Cohen, Chief Medical Officer, Braeburn

    Andrea Small-Howard

    Andrea Small-Howard, President & Chief Science Officer, GB Sciences, Inc.

    Lynn Kirkpatrick

    Lynn Kirkpatrick, President and CEO, Ensysce Biosciences Inc.

    Arun Bhaskar

    Arun Bhaskar, President, The British Pain Society

    16:30 Chair's Closing Remarks and Close of Day Two

    Richard Malamut

    Richard Malamut, Chief Medical Officer and EVP, Collegium Pharmaceuticals

    +

    FEATURED SPEAKERS

    Andrea Small-Howard

    Andrea Small-Howard

    President & Chief Science Officer, GB Sciences, Inc.
    Arun Bhaskar

    Arun Bhaskar

    President, The British Pain Society
    Candler Paige

    Candler Paige

    Chief Executive Officer, Doloromics
    Domenico Merante

    Domenico Merante

    Clinical Development Lead of Nephrology and Orphan Diseases, Vifor Pharma Ltd
    Geert Jan Groeneveld

    Geert Jan Groeneveld

    CSO/CMO, Centre for Human Drug Research
    Ilona Steigerwald

    Ilona Steigerwald

    Chief Medical Officer, SVP, Neumentum
    Jennifer Beierlein

    Jennifer Beierlein

    Health Program Specialist, National Institute of Neurological Disorders and Stroke National Institutes of Health
    Joshua Cohen

    Joshua Cohen

    Chief Medical Officer, Braeburn
    Lynn Kirkpatrick

    Lynn Kirkpatrick

    President and CEO, Ensysce Biosciences Inc.
    Maria  Maiaru

    Maria Maiaru

    Lecturer in Pharmacology, University of Reading
    Mark J. Field

    Mark J. Field

    CEO & Founder, EptivA Therapeutics
    Michael Seminerio

    Michael Seminerio

    Senior Director, US Medical Lead, Teva Pharmaceuticals
    Randall Kaye

    Randall Kaye

    Chief Medical Officer, Neurana Pharmaceuticals
    Richard Malamut

    Richard Malamut

    Chief Medical Officer and EVP, Collegium Pharmaceuticals
    Steve Fox

    Steve Fox

    Chairman, Akelos Inc
    Todd Krueger

    Todd Krueger

    President and CEO, AOBiome

    Andrea Small-Howard

    President & Chief Science Officer, GB Sciences, Inc.
    Andrea Small-Howard

    Arun Bhaskar

    President, The British Pain Society
    Arun Bhaskar

    Barbara Karp

    Program Director, EPPIC-Net, National Institutes Of Health
    Barbara Karp

    Candler Paige

    Chief Executive Officer, Doloromics
    Candler Paige

    Domenico Merante

    Clinical Development Lead of Nephrology and Orphan Diseases, Vifor Pharma Ltd
    Domenico Merante

    Geert Jan Groeneveld

    CSO/CMO, Centre for Human Drug Research
    Geert Jan Groeneveld

    Ilona Steigerwald

    Chief Medical Officer, SVP, Neumentum
    Ilona Steigerwald

    Jennifer Beierlein

    Health Program Specialist, National Institute of Neurological Disorders and Stroke National Institutes of Health
    Jennifer Beierlein

    Joshua Cohen

    Chief Medical Officer, Braeburn
    Joshua Cohen

    Julio Reinecke

    Chief Scientific Officer and Co-Founder, Orthogen A G
    Julio Reinecke

    Luda Diatchenko

    Canada Research Chair in Human Pain Genetics, McGill University
    Luda Diatchenko

    Lynn Kirkpatrick

    President and CEO, Ensysce Biosciences Inc.
    Lynn Kirkpatrick

    Maria Maiaru

    Lecturer in Pharmacology, University of Reading
    Maria  Maiaru

    Mark J. Field

    CEO & Founder, EptivA Therapeutics
    Mark J. Field

    Michael Seminerio

    Senior Director, US Medical Lead, Teva Pharmaceuticals
    Michael Seminerio

    Peter Wehling

    CEO and Founder, Orthogen A G
    Peter Wehling

    Randall Kaye

    Chief Medical Officer, Neurana Pharmaceuticals
    Randall Kaye

    Richard Malamut

    Chief Medical Officer and EVP, Collegium Pharmaceuticals
    Richard Malamut

    Ru-Rong Ji

    Professor in Anesthesiology, Distinguished Professor of Anesthesiology, Professor in Neurobiology, Professor in Cell Biology, School of Medicine,, Duke Neurobiology
    Ru-Rong Ji

    Steve Fox

    Chairman, Akelos Inc
    Steve Fox

    Todd Krueger

    President and CEO, AOBiome
    Todd Krueger

    Sponsors

    Official Media Partner

    Supporters

    Workshops

    Molecular and cellular pathophysiology of pain resolution
    Workshop

    Molecular and cellular pathophysiology of pain resolution

    Copthorne Tara Hotel
    6th May 2022
    London, United Kingdom

    VENUE

    Copthorne Tara Hotel

    Scarsdale Place, Kensington, London, United Kingdom

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
    HOTEL BOOKING FORM

    Past Presentation - Tina Doshi, John Hopkins University

    Download

    Past Presentation - Randall Kaye, Neurana Pharmaceuticals

    Download

    Past Presentation - Orna Green, Clexio Biosciences

    Download

    Past Presentation - Neil Singla, Lotus Clinical Research LLC

    Download

    Past Presentation - Max Mirza, Sygnature Discovery

    Download

    Past Presentation - David Thomas, NIH

    Download

    Sponsors


    Centre for Human Drug Research

    Sponsors
    http://www.chdr.nl/

    Since 1987, CHDR has developed into a unique research organisation specialising in early phase studies which combines knowledge and academic collaborations with operational excellence in clinical trial services. CHDR's strong track record in analgesic and pain research allows us to offer an efficient route towards proof of concept in patients.


    Media Partners


    ACNR

    Official Media Partner
    http://www.acnr.co.uk

    ACNR (Advances in Clinical Neuroscience & Rehabilitation) is one of the most widely read publications in the neurology field in the UK. It provides concise review articles, specialist reviews of core papers from international journals, conference news, book reviews, short accounts of best management practice, case reports, news of awards/appointments and more. This independently produced journal is available free of charge to members of the profession, and we welcome your input.

    Media Partners


    Pharmavision

    Supporters
    http://www.pharmavision.co.uk

    PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.


    Select Science

    Supporters
    http://www.selectscience.net/

    SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover impartial, expert opinion and trusted reviews about latest laboratory equipment and techniques; plus videos, application notes and science news from around the world. Become a member for free today.


    Hospital & Healthcare Management

    Supporters
    https://www.hhmglobal.com/media-pack



    Technology Networks

    Supporters
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    Contract Biotechnology

    Supporters
    http://www.contract-biotechnology.com

    Contract-Biotechnology.com is a web-based platform for laboratory outsourcing solutions. It is an online R&D matching tool that connects Scientifics and service and product providers worldwide. The platform Contract-Biotechnology.com would help you in the process of finding the right partner saving time and money, because with one single and secure application you would be able to receive multiple quotes quickly, keeping your contact information confidential. Contract-Biotechnology.com is the new Collaboration Network Model for Discovery Research and Development. Contract-Biotechnology.com team has extensive experience working for pharmaceuticals, biotechs, universities and academic research institutes and can help you addressing your key gaps.


    Drug Development Technology

    Supporters
    http://www.drugdevelopment-technology.com

    Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.


    International Pharmaceutical Industry

    Supporters
    http://www.ipimediaworld.com

    IPI gives you an insight into all areas of Biopharm, Medical, Pharmaceutical and Healthcare. IPI provides a proven supportive means of communication to the Pharmaceutical, Bio Pharmaceutical, Nutraceutical and Medical Devices industry, incorporating the latest in research and technology innovations, regulatory guidelines, marketing and communication strategies.


    Biocompare

    Supporters
    http://www.biocompare.com

    Biocompare.com is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. Biocompare combines an in-depth knowledge of life science products and new technologies with the power of the Internet to offer scientists the most dynamic, relevant, and innovative media-based marketplace for life science information.


    Mednous

    Supporters
    http://www.MedNous.com

    MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com


    Pharmaceutical Technology

    Supporters
    http://www.pharmaceutical-technology.com

    Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.


    Drug Discovery Today

    Supporters
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SMi.
    Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out